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Abstract
Background and Aims: The prevalence of hepatitis C virus (HCV) antibodies in Germany has been estimated to be in the
range of 0.4–0.63%. Screening for HCV is recommended in patients with elevated ALT levels or significant risk factors for
HCV transmission only. However, 15–30% of patients report no risk factors and ALT levels can be normal in up to 20–30% of
patients with chronic HCV infection. The aim of this study was to assess the HCV seroprevalence in patients visiting two
tertiary care emergency departments in Berlin and Frankfurt, respectively.
Methods: Between May 2008 and March 2010, a total of 28,809 consecutive patients were screened for the presence of anti-
HCV antibodies. Anti-HCV positive sera were subsequently tested for HCV-RNA.
Results: The overall HCV seroprevalence was 2.6% (95% CI: 2.4–2.8; 2.4% in Berlin and 3.5% in Frankfurt). HCV-RNA was
detectable in 68% of anti-HCV positive cases. Thus, the prevalence of chronic HCV infection in the overall study population
was 1.6% (95% CI 1.5–1.8). The most commonly reported risk factor was former/current injection drug use (IDU; 31.2%) and
those with IDU as the main risk factor were significantly younger than patients without IDU (p,0.001) and the male-to-
female ratio was 72% (121 vs. 46 patients; p,0.001). Finally, 18.8% of contacted HCV-RNA positive patients had not been
diagnosed previously.
Conclusions: The HCV seroprevalence was more than four times higher compared to current estimates and almost one fifth
of contacted HCV-RNA positive patients had not been diagnosed previously.
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Introduction
Chronic infection with the hepatitis C virus (HCV) affects an
estimated 2–3% of the world’s population and is a leading cause of
cirrhosis and hepatocellular carcinoma [1]. With the former
standard of care, a combination of pegylated interferon-alfa plus
ribavirin, the virus could be permanently eradicated in 42–46% of
patients with HCV genotype 1 only [2,3]. However, with the
addition of recently approved direct-acting HCV protease
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41206inhibitors, treatment success rates have been substantially
improved by approximately 20–40% [4,5,6,7].
Patients with advanced liver fibrosis or cirrhosis are less likely
to be cured compared to those without relevant fibrosis [8].
Moreover, chronic HCV infection is asymptomatic in the majority
of patients and diagnosis is therefore often delayed until more
advanced stages of fibrosis are present. Thus, early diagnosis is
desirable to optimize overall treatment success. Despite this,
national screening programs and surveillance systems are largely
heterogeneous across Europe, with reported HCV antibody
prevalences ranging from 0.4% to 3.5% by country and from
0.2% to 10.4% by region within countries [9]. Differences in
prevalence are largely attributed to variances in transmission
routes and differences in public health policies [10].
In Germany, the HCV seroprevalence has been estimated to be
in the range of 0.4–0.63% in the general population according to
two community-based studies conducted in 1993 to 1996 and
1998, respectively [11,12,13]. In clinical practice, HCV antibody
testing is routinely performed in risk populations only (e.g. blood
donors, injecting drug users etc.) and in those with unexplained
liver enzyme elevations [14]. However, it has been reported that
an estimated 15–30% of patients with chronic HCV do not report
any risk factors [15] and approximately 20–30% are reported to
have persistently normal liver enzymes [16,17,18]. Therefore, the
number of unreported cases, especially in metropolitan areas with
many high-risk groups, may be much higher than previously
assumed.
The aim of this study was to assess the prevalence of anti-HCV
antibodies, HCV-RNA and associated risk factors in patients
visiting emergency departments of two urban, tertiary care
hospitals.
Materials and Methods
Study population
The study was conducted in compliance with the declaration of
Helsinki and approval was obtained from the Ethics Committee of
the Charite ´ – Universita ¨tsmedizin, Berlin, Germany and the
Ethics Committee of the Medical Faculty of the J. W. Goethe
University, Frankfurt, Germany. In accordance with the Ethics
Committees requirements at the two participating study sites,
patients were informed of the study procedure and a notice was
displayed on a board.
Between May 2008 and October 2009, excess serum was
retained from all consecutive patients of 18 years of age or older
who presented to the internal medicine and traumatology
emergency departments at the Charite ´, Campus Virchow-
Klinikum in Berlin and who had a blood sample taken as part
of their routine diagnostic work up. In addition, excess serum was
also retained from consecutive patients of 18 years of age or older
who presented to the J. W. Goethe University Hospital emergency
department in Frankfurt between September 2009 and March
2010.
Demographic data, including age, gender, ethnicity and routine
laboratory values, including serum aminotransferase levels were
collected from hospital admission charts, where available. Upper
limit of normal (ULN) values for alanine aminotransferase and
aspartate aminotransferase levels were defined as 35 U/mL in
females and 50 U/mL in males.
HCV antibody screening and sample interpretation
HCV antibody screening of blood samples was performed on
the same day they were drawn using a fully automated
electrochemiluminescence immunoassay (ElecsysH Anti-HCV
immunoassay; Roche Diagnostics, Penzberg, Germany) on a
cobas e 601 platform. Serum samples with a signal/cut-off (s/co)
ratio ,0.9 were considered non-reactive, those with a s/co ratio
$1.0 were considered reactive, and samples with results between
0.9 and ,1.0 were interpreted as indeterminate.
All samples tested positive or indeterminate by the Elecsys Anti-
HCV immunoassay were subsequently stored at 220u to 225uC
and retested with the ARCHITECT anti-HCV test (Abbott
Diagnostics, Wiesbaden, Germany), a fully automated chemilu-
minescence micro particle immunoassay within 1–5 days. AR-
CHITECT results were interpreted as non-reactive (s/co ,1) or
reactive (s/co $1).
Samples with reactive results according to both assays were
considered anti-HCV positive, samples that were interpreted as
reactive by the Elecsys assay but non-reactive by the ARCHI-
TECT assay were counted as inconsistent results (IR).
HCV-RNA testing and genotyping
Samples with reactive anti-HCV results according to both
assays were further tested for the presence of HCV-RNA using the
real-time PCR-based COBAS Ampliprep/COBAS TaqMan
HCV-RNA assay (Roche Diagnostics, Penzberg, Germany; lower
limit of quantitation, 15 IU/mL), if sufficient stored (220 to 225u
C) left-over serum was available. IR samples were also tested for
HCV-RNA, depending on availability of leftover serum. Samples
with detectable but non-quantifiable HCV-RNA results (i.e.
,15 IU/mL) were considered HCV-RNA positive.
In Berlin HCV genotyping was performed on samples with
sufficient leftover volume and viral load (.1000 IU/mL) using the
VERSANT HCV Genotype 2.0 line probe assay (LiPA; Siemens
Healthcare Diagnostics, Eschborn, Germany). In Frankfurt known
genotypes were recorded from patient charts. Genotyping on these
patients had also been performed with the VERSANT HCV
Genotype 2.0 line probe assay.
All assays used in this study were performed and interpreted
according to the manufacturer’s instructions.
Patient contacting, risk factors and HCV awareness
Patients with reactive anti-HCV antibody results were contacted
by telephone and/or mail and appropriate diagnostic and
therapeutic follow-up was offered. In addition, knowledge of
HCV antibody status, presence of risk factors, disease history and
past antiviral therapies were recorded at the Berlin study site.
Furthermore, the presence of risk factors for possible HCV
infection was also recorded in a random sample of 391 anti-HCV
negative patients who served as controls and risk factors were
subjected to logistic regression analysis based on 936 patients (anti-
HCV positive in Berlin, n=535; anti-HCV negative, n=391).
Age and gender distribution in the control group was similar to
that in the overall anti-HCV negative population.
At the Frankfurt study site, only knowledge of HCV antibody
status was recorded.
In Germany, newly diagnosed patients with HCV infection
have to be reported to local health authorities and, ultimately, to
the Robert Koch Institute, a federal institution for disease control
and prevention. Therefore, all newly diagnosed patients were also
notified by the local health authorities to ensure appropriate
follow-up.
Statistical analyses
Clinical and laboratory characteristics of patients were ex-
pressed as mean 6 standard deviation or median and range, as
appropriate. Unadjusted prevalence was calculated and 95%
confidence intervals were based on a binominal distribution.
HCV Prevalence in Emergency Department Patients
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exact test for categorical variables and Mann-Whitney U-test for
continuous variables, as appropriate. Correlations between vari-
ables were performed using Spearman’s correlation coefficients.
To test for associations between risk factors for HCV infection and
HCV seropositivity, univariate and multivariate models were
employed. For all tests, a p-value of less than 0.05 was judged to be
statistically significant.
All statistical analyses were performed using BiAS for Windows,
version 9.08 (epsilon 2010, Frankfurt, Germany) or IBM SPSS
Statistics for Windows, version 19.0 (SPSS/IBM, Somers, NY,
USA).
Results
Anti-HCV antibody prevalence and patient characteristics
A total of 28,809 patients (52% males, mean age,
51.9620 years) were screened for the presence of anti-HCV
antibodies at the two participating study sites. Of these, 1,060
patients (3.7%; 95% CI: 3.5–3.9) were tested positive for the
presence of anti-HCV antibodies with the Elecsys Anti-HCV
assay. Subsequent retesting of anti-HCV antibody positive and
indeterminate patient samples with the ARCHITECT anti-HCV
assay confirmed the presence of anti-HCV antibodies in 757/
1,060 (71.4%) cases. Thus, an overall prevalence of 2.6% (95% CI:
2.4–2.8) was recorded, 2.4% (95% CI: 2.2–2.6; n=535/22,490) at
the Berlin study site and 3.5% (95% CI: 3.1–4.0; n=222/6,319) in
Frankfurt. Screening results according to the different study sites
and distribution among internal medicine and traumatology
emergency departments are shown in Table 1. Whereas signifi-
cantly more anti-HCV positive patients were visiting the internal
medicine wards (2.7% vs. 2.4%; p,0.001), the number of HCV-
RNA positive patients was higher among those visiting the trauma
departments (71% vs. 67%; p,0.001).
The highest anti-HCV prevalence was found in patients aged
40–59 (4.1%). Thirty-eight and 24 patients, respectively, needed to
be screened to identify one anti-HCV positive patient in the
overall study population and in patients aged 40–59 only. Among
anti-HCV positive patients, males were significantly younger than
females (p,0.001) and peaks were observed in males aged 40–
59 years and in females aged $60 years. The majority of anti-
HCV positive patients were of German origin (67.8%) and Eastern
Europeans made up the largest group among immigrants (11.2%;
Table 2).
Of all HCV seropositive patients, 65% knew that they were or
had been infected. Knowledge of HCV status was significantly
higher in those with confirmed chronic HCV infection compared
to those who were seropositive only (p=0.0096) and significantly
more patients with chronic HCV infection from Frankfurt were
aware of their status compared to patients from Berlin
(p=0.0161). Patient characteristics according to serostatus and
nucleic acid analysis are presented in Table 2.
HCV-RNA analysis and genotype distribution
Among the 757 patient samples with positive anti-HCV results,
685 (90.5%) were available for HCV-RNA testing. In addition,
HCV-RNA testing was also performed in 85 patients with
inconsistent serologic results (Elecsys positive/ARCHITECT
negative).
HCV-RNA was detectable in 465/685 (67.9%) anti-HCV
positive patients (Table 1). Thus, the prevalence of chronic
hepatitis C infection in the overall study population was 1.6%
(95% CI 1.5–1.8; n=465/28,809). Among HCV-RNA positive
patients, 41 (Berlin, n=40; Frankfurt, n=1) had detectable viral
load levels below the assay’s limit of quantitation (i.e. ,15 IU/
mL). Among the 85 patients with inconsistent serologic results, 5
had positive HCV-RNA results ,15 IU/mL whereas the
remaining patients were HCV-RNA negative.
Forty-two patients (26.8%) from the Berlin study site who tested
positive for anti-HCV antibodies but negative for HCV-RNA
reported a history of antiviral treatment. The remaining 115
(73.2%) patients had either cleared HCV-RNA spontaneously or
they had false positive anti-HCV results. However, as all 115
patients had concordant positive anti-HCV results according to
both assays, spontaneous clearance may have been more likely.
HCV genotype 1 was the most prevalent genotype (65.6%,
n=210) in HCV-RNA positive patients, followed by genotype 3
(19.1%; n=61) and 2 (5.3%; n=17).
Liver enzymes
Alanine aminotransferase (ALT) and/or aspartate aminotrans-
ferase (AST) levels were determined in 656 (87%) of anti-HCV
antibody positive patients. Elevated ALT and/or AST levels were
present in 52% of patients only. However, in patients with
detectable HCV-RNA, 61% had elevated ALT/AST levels and
this was significantly more compared to those with anti-HCV only
(32%; p,0.001). However, elevated ALT/AST levels were poorly
correlated with chronic HCV infection (r=0.27, p,0.001). When
specifically looking at patients with negative HCV-RNA, there was
no difference in BMI, alcohol or nicotine use between patients
with or without ALT/AST elevation (data not shown).
Risk factors
Typical risk factors for HCV transmission were recorded in
319/535 (60%) patients at the Berlin screening site (Table 3).
Current or former IDU was reported as the primary risk factor for
HCV infection in 167 patients (31%). Other risk factors included a
surgical procedure before 1992 (when commercial anti-HCV
serological testing became available; 19%), past history of blood
transfusion before 1992 (9%), past history of solid organ
transplantation (8%), hemodialysis (4%) and coagulation disorders
(2%).
Table 1. Distribution of anti-HCV and HCV-RNA status for
each of the two study sites alone and all patients combined.
Study site all patients Berlin Frankfurt
Number of patients screened 28,809 22,490 6,319
HCV status, n (%)
anti-HCV+ 757 (2.6) 535 (2.4) 222 (3.5)
HCV-RNA+ (% of tested) 465/685 (68) 346/503 (69) 119/182 (65)
HCV-RNA2 (% of tested) 220/685 (32) 157/503 (31) 63/182 (35)
Internal ER, n (%) 20,642 (72) 17,024 (76) 3,618 (57)
anti-HCV+ 562 (2.7) 399 (2.3) 163 (4.5)
HCV-RNA+ (% of tested) 337/504 (67) 253/373 (68) 84/131 (64)
HCV-RNA2 (% of tested) 167/504 (33) 120/373 (32) 47/131 (36)
Trauma ER, n (%) 8,167 (28) 5,466 (24) 2,701 (43)
anti-HCV+ 195 (2.4) 136 (2.5) 59 (2.2)
HCV-RNA+ (% of tested) 128/181 (71) 93/130 (72) 35/51 (69)
HCV-RNA2 (% of tested) 53/181 (29) 37/130 (28) 16/51 (31)
Serum samples for HCV-RNA analysis were available from 685 out of 757 anti-
HCV positive patients.
doi:10.1371/journal.pone.0041206.t001
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PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41206Univariate analysis showed that current or former IDU, surgical
procedures before 1992, past history of blood transfusion before
1992 and elevated liver enzymes were all associated with anti-
HCV seropositivity. Risk factors that remained independently
associated with anti-HCV seropositivity in the multivariate
analysis included past history of blood transfusion before 1992
(OR=15.5, 95% CI: 4.7–51.7, p,0.001) and elevated liver
enzymes (OR=3.0 1.3–7–4, p=0.02).
Patients with IDU as the main risk factor were significantly
younger than those without IDU (p,0.001) and the male-to-
female ratio was 72% (121 vs. 46 patients; p,0.001). Furthermore,
patients with IDU had been diagnosed more often prior to the
current screening program (90%), while those without IDU had
not been diagnosed in 41% of cases.
Eligibility for antiviral treatment
Five hundred and fourteen out of 535 HCV seropositive
patients (96%) from Berlin were contacted by phone or in writing.
Of these, 175 (33%) followed our invitation to get expert advice in
our hepatology outpatient clinic. Among patients not previously
seen in our clinic, 48 had confirmed chronic HCV infection and
28 (5%) were considered eligible for antiviral treatment while 20
had medical conditions precluding them from pegylated interfer-
on/ribavirin therapy (e.g. drinking problem, active IDU, moder-
ate-to-severe depression; Figure 1).
Discussion
Comprehensive epidemiological data on HCV prevalence and
associated risk factors are limited. Recent findings suggest that
HCV seroprevalence rates in Germany vary significantly by
region, with higher prevalence rates in Western Germany
compared to Eastern Germany and in urban versus rural areas
[19,20]. These regional variations may have direct implications for
federal and local public health measures regarding prevention and
control of HCV infection.
To our knowledge, our study represents the largest prospective
data analysis on HCV prevalence in patients admitted to
emergency departments worldwide.
We applied a two-step screening approach, using the Elecsys
Anti-HCV assay as the primary screening test followed by
confirmatory testing with the Architect Anti-HCV assay in all
Elecsys-positive and indeterminate samples. An assay comparison
study was not intended. However, with the Architect serving as the
reference assay, Elecsys Anti-HCV had a specificity of 99% at the
two participating study sites as was also observed in a recent assay
validation study [21]. Interestingly, all specimens with inconsistent
anti-HCV results (Elecsys positive/ Architect negative) that were
later tested for the presence of HCV-RNA (n=85), yielded
negative or ,15 IU/mL PCR results. It must be noted, however,
that previous studies had not shown lower sensitivities for the
Elecsys assay in comparison to competitor assays [21,22] and our
results should be interpreted with caution as no head-to-head assay
comparison was performed.
The main finding of our study was that the HCV seropreva-
lence was 2.6% (95% CI: 2.4–2.8) at our two institutions
combined, which is more than four times higher than the
estimated prevalence in the general German population [11,12].
The prevalence was higher in Frankfurt (3.5%) compared to Berlin
(2.4%). The overall high HCV prevalence may be partly explained
by the urban study setting as well as the fact that high-risk
populations (e.g., injecting drug users, homeless people and other
patients not enrolled in regular health plans) were not excluded
from our study. Other risk groups (e.g., patients with coagulation
disorders or liver transplant candidates) may even have been
overrepresented as they are regular visitors to tertiary care
university hospitals and thus may account for selection bias.
In the past, HCV seroprevalence estimates have been
performed in different populations and regions but usually
involved considerably lower sample sizes [10,23,24]. In a study
comprising 2,523 patients who presented to the emergency
department at a university hospital in Baltimore, USA, in 1988,
the HCV seroprevalence was found to be 18% with a particularly
high prevalence among minorities [23]. However, nucleic acid
testing was not available at that time and antiviral treatment was
still in the early stages of development [25]. In a more recent study
from Switzerland [24], the anti-HCV prevalence among 5,036
patients who were admitted to the emergency department of a
university hospital in Berne was calculated to be 2.7%, and this is
in line with our own findings. However, in that study, HCV-RNA
was tested in 15.6% of anti-HCV positive patients only and thus,
little information on persisting HCV infection was available.
Another important finding of our study is that the proportion of
patients with detectable HCV-RNA was 68%, which is lower than
that found in the German National Health Survey (84%)
conducted in 1998 [12]. Interestingly, a similar decline was
recently reported from France where the proportion of HCV-
RNA positivity among anti-HCV positive adults aged 20–59 years
declined from 81% in 1994 to 57% in 2004 and this was most
likely attributable to an increased treatment activity [26].
Although increased treatment activity has also been reported
from Germany, our own data may not be directly comparable
with those obtained in the French population-based study.
Analysis of genotype distribution in HCV-RNA positive patients
yielded similar results to those of a recent comprehensive analysis
in 9,455 patients from different parts of Germany [19]. That is,
genotype 1 was the type most commonly found in our study
population (66%), followed by genotype 3 (19%) and 2 (5%).
However, in line with a shift in infection sources, decreasing
numbers of HCV genotype 1b (the genotype most commonly
associated with transmission via blood transfusions) infections and
increasing prevalence of HCV genotype 3 (the genotype most
commonly associated with IDU) have been reported [19].
In line with previous findings [19,27,28], the anti-HCV
prevalence was higher in males than in females at both study sites,
Table 3. Self-reported risk factors for HCV transmission in the
anti-HCV positive population at the Berlin study site.
Risk factor, n (%)
Any risk factor 319 (59.6)
IVDU 167 (31.2)
Surgical procedure before 1992 103 (19.3)
Transfusion of blood products before 1992 48 (9.0)
Solid organ transplantation 45 (8.4)
Haemodialysis 20 (3.7)
Health care worker 16 (2.2)
Sexual contact with HCV infected person 8 (1.5)
Coagulation disorder 7 (1.3)
Prison inmate 2 (0.4)
IVDU, intravenous drug-use.
Multiple responses were possible. Percentages are given in relation to all anti-
HCV positive patients (n=535).
doi:10.1371/journal.pone.0041206.t003
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aged 40–59 years (4.1%). This may be explained by gender-specific
risk behavior, as IDU and, more recently, sexual transmission have
been found to be more frequent in men whereas the majority of
women may have been infected via transfusion of blood products or
anti-D prophylaxis by immunoglobulin prior to the commercial
introduction of anti-HCV screening tests in the early 1990s
[29,30,31,32]. Interestingly, the two aforementioned German
community-based studies found a higher, albeit not significant
HCV seroprevalence in females, indicating that IDUs may have
been underrepresented in these studies.
In our study, patients with a migration background from
Eastern Europe made up the largest group of non-German anti-
HCV carriers and this is in line with previous findings [19]. Recent
population based anti-HCV prevalence estimates from former
Communist countries were up to 8–9 times higher compared to
Germany, ranging from 1.5–2% in Poland and the Czech
Republic to 3.5% in Romania. The main reasons for these high
prevalence rates are believed to be infections due to blood
transfusions before 1995 and incomplete sterilized medical
equipment, which continues to be a source in rural areas [10].
The high proportion of anti-HCV positive patients from Eastern
Europe in our study most likely reflects the significant increase in
immigration from former Communist countries since 1990.
In a recent study, targeted age-based screening was suggested
based on a mathematical approach using a birth cohort of United
States residents born between 1946 and 1970 [33]. In their model,
McGarry and co-workers predicted a significant health benefit and
improved cost-effectiveness over risk-based screening programs
that are currently in use. Our own prevalence data may support
such an approach.
Contrary to previous findings, knowledge of HCV status was
high (78%) among anti-HCV positive patients and this may again
reflect the affiliation with university hepatology outpatient clinics.
In our study, almost one third of anti-HCV positive patients
who were contacted regarding risk behavior reported former or
current IDU. Indeed, IDU is currently believed to be the major
risk factor in most Western European countries where up to 90%
of HCV-infected patients have reported IDU as the primary
transmission factor [10]. Interestingly, the vast majority (90%) of
patients with a history of IDU had been diagnosed prior to our
study, indicating that effective screening measures are in place in
this particular patient population. In contrast, 41% of patients who
did not report IDU as a risk factor were unaware of their HCV
serostatus.
A further important finding of our study is that 39% of patients
with detectable HCV-RNA had normal serum aminotransferase
levels. This constitutes a much higher percentage than previously
reported [18,19] and may be of immediate clinical significance as
it supports the applicability of emergency departments as targets
for an increased screening activity, especially when taking into
account that one half of contacted anti-HCV positive patients did
not report any risk factors for HCV infection in our study.
Eligibility for treatment was only assessed in the Berlin patient
cohort. Here, out of 346 patients with chronic HCV infection, 28
(8%) were eligible for immediate antiviral therapy. This low
number may be explained by restrictive eligibility criteria and only
33% of anti-HCV positive patients were assessed in our
hepatology outpatient clinic whereas the majority of contacted
Figure 1. Study flow-chart showing outcome of the Berlin screening population with respect to eligibility for antiviral treatment.
Percentages are given in relation to anti-HCV positive patients (n=535).
doi:10.1371/journal.pone.0041206.g001
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physicians. Thus, these data should be interpreted with caution.
Our study has several limitations: First, due to the study setting
and design it cannot be extrapolated to the general German
population. Second, given the fact that not all patients who
presented to our emergency departments had a blood sample
taken, a possible recruitment bias needs to be taken into account.
Nevertheless, our data represent one of the largest cross-sectional
patient samples ever to be screened. Finally, the lack of a
structured patient questionnaire weakens our data on risk
behavior, knowledge of HCV serostatus and treatment eligibility.
In conclusion, our data provide evidence of a high HCV
seroprevalence among urban emergency department patients and
clearly support the importance of re-defining risk groups and
designing screening programs accordingly (e.g. birth-cohort
screening). In light of recently improved cure rates for chronic
HCV, expanding access to treatment should be encouraged.
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